SanFran,

In the news release, Zenith writes: "In the Phase 1 trial, Zenith will be evaluating the safety, pharmacokinetics, and efficacy of ZEN-3694 as a single agent and in combination with the current standard of care enzalutamide."

It sounds like they are grouping together both the ZEN003694 stand alone trial NCT02705469 and the ZEN003694/Enzalutamide trial NCT02711956 in that statement. I interpret the news release to indicate that they have now started dosing with the stand alone ZEN003694 but not the ZEN003694/Enzalutamide trial. This latter conclusion is based upon the timeline provided in the Jan 7th update as well as the fact that ClinicalTrials.gov doesn't list the ZEN003694/Enzalutamide as recruiting.

As you said, Don will clear this up on Monday.

BearDownAZ